Drug & Biologic Risk Assessment
Diligence on small molecules, biologics and cell and gene therapies across NDA, ANDA, 505(b)(2) and BLA pathways: trial design, endpoints, CMC and exclusivity. An automated Quick Screen within 24 hours; full reports in 48, reviewed by a physician and a biomedical engineer.
The Problem
Pivotal endpoints that look strong on paper can weaken under ICH E9(R1) estimand scrutiny. Patent protection can shorten when a paragraph IV challenge lands. CMC scale-up can delay a launch. Each is worth checking before an LOI.
Pivotal trial hit statistical significance, but the primary endpoint doesn't translate cleanly to labeling or payer coverage. Advisory committee reviews can turn on exactly this.
Regulatory exclusivity and patents are separate protections. NCE exclusivity runs five years, but an ANDA with a paragraph IV patent challenge can be filed at year four; orphan exclusivity covers only the approved orphan indication; pediatric exclusivity adds six months. A loss-of-exclusivity date in a pitch deck needs checking against the Orange Book.
A process validated at 100L doesn't always work at 10,000L. Bioreactor drift, fill-finish capacity, and single-source raw materials can delay a launch.
Standard of care moves between trial start and launch. Your active comparator may no longer be relevant, and payer coverage hinges on comparative effectiveness.
Accelerated approval, REMS, and confirmatory-trial obligations become expensive surprises. FDA's postmarketing requirements and commitments database is public, so a target's fulfillment record can be checked.
Under the IRA, a small-molecule drug can be selected for Medicare negotiation 7 years after approval, with the negotiated price taking effect at year 9; biologics at 11 and 13 years. Those dates belong in any revenue model the deal rests on.
Regulatory Pathways We Cover
An NDA isn't an ANDA isn't a 505(b)(2) isn't a BLA. Each has its own risk surface — reference listed drug integrity, trial-design acceptability, CMC bar, exclusivity arithmetic. A full report reads each on its own terms.
Full applications, including new molecular entities. Pivotal-trial integrity, endpoint strength, safety database, labeling negotiation, and post-marketing commitments drive the risk score.
Relies on published literature or listed reference drug. Risk sits in bridging studies, patent/exclusivity landmines, and reimbursement when the reference drug is genericized.
Bioequivalence-based. Risk is paragraph-IV Hatch-Waxman litigation, API supply, FDA CGMP inspection history, and margin compression on launch.
Protein therapeutics, mAbs, cell & gene therapies. CMC complexity, manufacturing scale, Purple Book reference-product exclusivity, and biosimilar exposure dominate.
What a Therapeutic Report Examines
Full reports read the same 20-category framework on every company and summarize it in a composite Vantage Index. For a drug or biologic, these are the areas that get the closest read. Some inputs, like financials, come from the company or the buyer.
| Domain | What we're looking at |
|---|---|
| Clinical Trial & Endpoint Integrity | Pivotal design, endpoint validity under ICH E9(R1), statistical plan, data monitoring, missing-data handling, comparator relevance |
| IP & Exclusivity Strategy | Composition-of-matter, method-of-use, formulation patents, Orange Book listing, orphan/NCE/pediatric exclusivity, paragraph-IV exposure |
| Regulatory Pathway Integrity | Pre-IND/EOP2/pre-NDA meeting minutes, special protocol assessment, breakthrough/fast-track/priority-review status, foreign regulatory alignment |
| CMC & Manufacturing | Process validation, API sourcing, fill-finish capacity, comparability protocols, PAI readiness, CDMO dependency, serialization |
| Reimbursement & Payer | ICER outlook, payer policy precedent, IRA Medicare negotiation exposure, 340B impact, part B vs D, comparative effectiveness positioning |
| Safety & Pharmacovigilance | Safety database size, adverse-event trends, REMS requirements, boxed-warning risk, post-marketing commitment history |
| Commercial & Market Access | Prescriber target, channel strategy, specialty pharmacy network, hub services, patient support programs, KOL engagement |
| Financial & Operational | Runway to approval, R&D spend discipline, licensing obligations, contingent value rights — provided by the company or buyer |
Pricing Ladder
Start with an automated Quick Screen, delivered within 24 hours of a complete intake. Move to a full report when the deal moves: 48-hour turnaround, reviewed by Arvind Ravinutala, MD, and Aswini Ravinutala, BME.
Running diligence across a fund or portfolio? See Vantage Licenses →
Want continuous monitoring post-close? Surveillance from $1,500/mo →
Therapeutic Intelligence Library
Articles on therapeutic risks in diligence. Written by Arvind and Aswini.
Staff cuts, the 2025 shutdown and user-fee reauthorization, and how to check a timeline against FDA's published review performance.
Read → Regulatory ShiftWhat FDA's revised general wellness and clinical decision support guidances changed for wearables and AI software, and what they did not.
Read → Early AssetClinical translation, business-model fit and commercial talent: the gaps that can stall a university spinout, and what to ask about each.
Read → Market AccessEligibility criteria, negotiation mechanics, the small biotech exception, and what a revenue model built before the IRA may leave out.
Read → ExclusivitySeven-year exclusivity tied to the approved use or indication, the Medicare negotiation exclusion, and the diligence questions for orphan-focused therapeutics.
Read → Post-MarketingPrograms accelerated on surrogate endpoints carry confirmatory-trial obligations. Since FDORA (2022), FDA has expedited procedures to withdraw an accelerated approval when confirmatory work falls short.
Read →Buy a Quick Screen and give us the target and a data-room link (or just a pipeline page) on the intake form. The Quick Screen arrives within 24 hours of a complete intake. Prefer to talk first? Book a free 20-minute call.